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PurityAbstract The present study provided a chemical, physical and physicochemical characterization of
myrsinoic acids A (MAA) and B (MAB) isolated from stem bark of Rapanea ferruginea Mez
(Myrsinaceae). In previous pre-clinical studies these compounds have shown important anti-
inﬂammatory, anticholinesterasic and antimicrobial activities. A gradient stability-indicating LC–
UV method was developed, and a forced degradation study was carried out. Purity, logP, solubil-
ity, and pKa were determined. Thermal analysis (DSC/TG) was conducted for both compounds.
MAB was characterized by X ray powder diffraction (XRPD) and scanning electron microscopy
(SEM). When submitted to stress conditions, both markers showed degradation, with MAA pre-
senting higher lability. The purity of MAA (oil) was 76.20%, while that of MAB (powder) was
98.90%. MAA and MAB exhibited logP values of 3.30 and 3.22, respectively. MAA was very
slightly soluble in methanol and acetonitrile, while MAB was slightly soluble in both solvents.
Both were practically insoluble in water. MAA and MAB showed pKa of 4.5 and 4.8, respectively.
In the SEM analysis, MAB showed a semi-crystalline morphology and high purity when analyzed
by XRPD and DSC. This data will contribute to the development, quality control and standardiza-
tion of pharmaceuticals using MAA and MAB.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prenylation consists of the addition of an isoprenoid side chain
to another molecule (Alhassan et al., 2014). A wide range of
pharmacological activities have been reported for prenylated
Structural and physicochemical characterization and purity assessment 873benzoic acids’ derivatives of secondary metabolites (Chen
et al., 2000; Flores et al., 2009; Malami, 2012; Seeram et al.,
1996). Phytochemical studies of the Rapanea genus have led
to the isolation of diprenylated benzoic acids (Blunt et al.,
1998) named myrsinoic acids A (3-geranyl-4-hidroxy-5-(30met
hyl-20-butenyl)-benzoic acid), B (5-carboxy-2,3-dihydro-2-(1,5
-dimethyl-1 hydroxy-4-hexenyl)-7-(3-methyl-2-butenyl)benzo
furan), C ((2S),(3S)-6-carboxy-2,3-dihydro-3-hidroxy-2-methy
l-2-(40-methylpenta-30-enyl)-8-(300-methyl-200-butenyl)-cromon),
E (3,5-digeranyl-4-hydroxy)-benzoic acid) and F (5-carboxy-2
,3-dihydro-2-(10,50-dimethyl-10E,40-hexadienyl)-7-(300-methyl
200-butenyl)-benzofuran), which have shown important anti-
inﬂammatory activities (Dong et al., 1999; Hirota et al.,
2002; Ito et al., 2008; Makabe et al., 2003). The structural
characterization by these authors consisted of NMR, IR and
EIMS techniques.
The presence of myrsinoic acids A, B and C was previously
identiﬁed in the extract of stem bark of Rapanea ferruginea
Mez (Myrsinaceae) (syn. Myrsine coriacea) (Baccarin et al.,
2011). These compounds showed anticholinesterasic activity
(Gazoni, 2009) and presented signiﬁcant antibacterial activity
against Staphylococcus aureus and Bacillus subtilis. MAA
and MAB also presented moderate toxic potential in the brine
shrimp test and were not mutagenic in Saccharomyces cere-
visiae (Bella-Cruz et al., 2013).
Myrsinoic acid A (MAA) Fig. 1A was an inhibitor of
mammalian DNA polymerases (Mizushina et al., 2000).
MAA showed facilitating action on the stages of memory
(acquisition, consolidation and evocation) in normal mice,
and also in mice with streptozotocin-induced Alzheimer’s dis-
ease (Costa et al., 2003).
Myrsinoic acid B (MAB) Fig. 1B exhibited methioninase
inhibitor activity from periodontal bacteria such as
Fusobacterium nucleantum, Porphyromonas gingivalis and
Treponema denticola (Ito et al., 2008). In addition, this com-
pound showed a signiﬁcant antinociceptive effect through
mechanisms that involve interaction with L-arginine–nitric
oxide, the serotonergic and cholinergic systems, and the a-
adrenoceptors (Hess et al., 2010). MAB administeredFigure 1 Structures of the myrsinoic acids A (A) and B (B).preventively or therapeutically, systemically or by the spinal
route, reduced mechanical and thermal hypersensitivity in mice
submitted to models of inﬂammatory and neuropathic pain,
shows an excellent potential to treat persistent pain in humans,
without any signiﬁcant side effects (Antonialli et al., 2012).
MAB exhibited pronounced leishmanicidal activity against
Leishmania amazonensis and Leishmania brasiliensis, suggest-
ing its importance as a possible source of antiparasitic agents
(Cechinel-Filho et al., 2013).
Considering the absence of physicochemical data and the
potential application ofMAA andMAB as phytodrugs, or pos-
sible drug leads, suitable for future optimization by medicinal
and synthetic chemists, the aim of this study was to provide a
chemical, physical and physicochemical characterization of
these compounds to assist in the quality control of its related
pharmaceutical products.2. Material and methods
2.1. Chemicals and reagents
Analytical grade hexane and ethyl acetate were purchased from
Vetec (Rio de Janeiro, Brazil). Deuterated chloroform (CDCl3)
was purchased from Merck (White House Station, NJ, USA).
For HPLC analysis, all solvents used were HPLC grade
(Tedia, Fairﬁeld, Ohio, USA). The water was puriﬁed using
a Milli-Q system (Millipore, Massachusetts, USA). All solu-
tions were ﬁltered through 0.45 lm membrane (Millipore,
Massachusetts, USA).
2.2. Isolation and puriﬁcation of myrsinoic acids A and B
Isolation procedures were performed according to Hess et al.
(2010) and Bella-Cruz et al. (2013) as brieﬂy described below:
a mixture of hydroethanolic extracts of stem bark, branches
and leaves of R. ferruginea (43 g) was subjected to silica gel col-
umn chromatography with hexane/ethyl acetate to obtain
myrsinoic acids A and B in their pure forms. The fractions
eluted with 20% and 40% of ethyl-acetate in hexane gave
MAA (2.3 g), and MAB (4.2 g), respectively. After solvent
evaporation, MAA presented as a yellow oil, and MAB as a
crystalline white powder.
2.3. Structural characterization
2.3.1. Nuclear magnetic resonance 1H and 13C
NMR spectra were measured on a Bruker AC-300F
300 MHz. Hydrogen nuclear magnetic resonance (1H NMR)
and Carbon-13 nuclear magnetic resonance (13C NMR) spec-
tra were recorded using CDCl3 as solvent. Chemical shifts were
referenced to the residual solvent peak, or to tetramethylsilane
(TMS) as an external reference. The data were reported in
terms of chemical shift (d, in ppm), multiplicity, coupling
constant (J, in Hz), and integrated intensity. The multiplicity
of a particular signal was indicated as s (singlet), d (doublet),
t (triplet), or m (multiplet).
2.3.2. Fourier transform infrared spectroscopy (FTIR)
FTIR spectra were recorded on a FT-IR Shimadzu IR
Prestige-21. A fourier transform infrared spectroscopy
874 T. Zermiani et al.equipped with an attenuated total reﬂectance (ATR) accessory
was used to obtain infrared spectra of MAA. FTIR analysis of
MAB was carried out using diffuse reﬂectance spectroscopy
DRS-FTIR with KBr. Each spectrum was obtained from
3600 to 700 cm1.
2.3.3. Raman spectroscopy
The Raman experiment was carried out in a PeakSeeker 785
(RAM-PRO-785). The Raman system was operated with a
diode laser of 785 nm and 300 mW at the source. The collected
Raman radiation was dispersed with a grating and focused on
a Peltier-cooled charge-coupled device allowing a spectral
resolution of 6 cm1 to be obtained. The laser was focused
on the sample by the 4· objective lens of a microscope, giving
a spot of approximately 2 lm diameter. All spectra were
recorded in the spectral window of 200–1800 cm1 with the
same acquisition time (30 s). The MAB sample was analyzed
on a glass slide at room temperature.
2.3.4. Ultraviolet spectroscopy
UV spectra were measured in samples at a concentration of
50 lg mL1 using methanol as solvent. Speciﬁc absorption
(E1%1cm)was calculated at 260 nmforMAA, and270 nm forMAB.
2.3.5. Mass spectrometry with direct sample inlet (DI-MS)
MS spectra were measured on a Shimadzu DI-2010 direct sam-
ple inlet accessory that was attached to a GC2010 GC/MS
(Shimadzu, Kyoto, Japan). The mass spectrometer was
operated in electron ionization positive mode. The sample
was directly introduced into the ion source, for which the
temperature was set to 250 C.
2.4. HPLC analysis
Chromatographic analysis was carried out on a HPLC
ShimadzuLC 20-AT system, consisting of a quaternary pump
and a Shimadzu SPD-M20A photodiode array detector, SIL-
20AHT auto-sampler, with a Shimadzu CTO-10ASVT column
oven equilibrated at 35 C, and software LC Solution was used.
The chromatographic column used was Phenomenex Kinetex
C18 column (150 · 4.6 mm) with core-shell particles of 2.6 lm.
The separation was achieved on a gradient method. Themethod
was chosen according to the best separation of myrsinoic acids
A and B at a concentration of 50 lg mL1 in methanol solution.
The best mobile phase was methanol–acetonitrile–water (acidi-
ﬁed to pH 2.5 with phosphoric acid) at a ﬂow rate of
0.9 mL min1. The gradient elution was programmed as
follows: initial isocratic condition during 2 min (25:5:70),
2–5 min (25:30:45), 5–10 min (25:60:15), 10–12 min (20:70:10),
12–15 min (15:75:10) and 15–20 min (15:84:1) then returns to
the initial condition until 30 min of analysis. The analysis was
monitored at 260 nm for MAA and at 270 nm for MAB. The
purity of MAA and MAB was calculated through the presence
of other peaks in the chromatograms of the compounds,
expressed in relative area.
The speciﬁcity of the method was established according to
the ICH guidelines (2005) using the PDA detector for the peak
purity evaluation, and the samples were analyzed under forced
degradation conditions (acidic, alkaline, oxidative and pho-
todegradation), as described below.2.5. Stability data
In order to develop a gradient stability-indicating LC–UV
method, a forced degradation study of MAA and MAB was
carried out. Both compounds were initially dissolved in metha-
nol (50% of the volume) and the volume was made up with the
degraded solutions as follows: hydrolytic stress studies were
performed (at 25 C) in acid (1 M HCl, 24 h), basic (1 M
NaOH, 24 h) and oxidative (30% H2O2, 6 h) conditions, at
ﬁnal concentration of 100 lg mL1 solutions of MAA and
MAB. The MAA oil and MAB powder were submitted under
conditions of visible light (2.4 mi lux h1) and UVA
(400 W h m2) irradiation. After exposure, sample solutions
of 100 lg mL1 in methanol were analyzed by the HPLC
method. The stressed samples were assayed by comparison
with non-degraded reference standards.
To conﬁrm the temporal stability of MAA and MAB in
methanol and acetonitrile, 2.5 mg of each sample was weighted
and dissolved in 25 mL of each solvent. The solutions were
stored in the following three conditions: light shielding at room
temperature, light shielding at 15 C and light shielding at
2 C. The sampling periods were 0, 4, 8, 24, 48 h and 14 days.
Each sample was evaluated by HPLC. Statistical analysis was
carried out by one-way ANOVA using experimental design
tools of Statistica 6.0 software followed by Tukey test. The
level of signiﬁcance used was p< 0.05.
2.6. Physicochemical characterization
2.6.1. Log P
The octanol/water partition coefﬁcient (logP) was measured
according to OECD guideline n. 117 (1989), which uses the
HPLC technique. The reference substances used were benzyl
alcohol, phenol, benzoic acid, benzene, toluene and naphtha-
lene. The injections (20 lL) were carried out on a
Phenomenex (Torrance, California, USA) C18 3 lm Fusion
RP 100 A˚ (150 mm · 4.6 mm), the mobile phase consisted of
80:20 (v/v) methanol–water (pH 3.00, phosphoric acid) and
the elution occurred in isocratic conditions, at a ﬂow rate of
1.0 mL min1, and detection at 210 nm. Capacity factors (k)
of each substance were obtained by the following expression:
k ¼ tR  t0
t0
where tR is the retention time of the test substance, and t0 is the
dead-time. The k value and their respective logP were corre-
lated on analytical curve (logk versus logP of the reference
substances) and analyzed by linear regression. To determine
the myrsinoic acids A and B logP, solutions with concentra-
tion of 50.0 lg mL1 were injected in the same chromato-
graphic conditions, and the k value of each compound was
determined and then input into the straight line equation.
2.6.2. Solubility
The solubility of myrsinoic acids A and B was designed to com-
ply with pharmacopoeic speciﬁcations (The United States
Pharmacopeia, 2012). This parameter was tested for methanol,
acetonitrile and water. Increasing amounts of each standard
were added to a ﬁxed volume of solvents to obtain saturated
solutions. The supernatant was ﬁltered through a 0.45 lm ﬁlter.
The drug concentration was determined byHPLC (Section 2.4).
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Conformational analysis was carried using the Spartan soft-
ware (Wavefunction Inc., Irvine, California, USA). Density
Functional Theory (DFT) was performed on Gaussian 09
software. The pKa prediction was performed using Maestro,
version 9.4 (Schrodinger New York, NY, 2013) software.
2.6.4. Thermogravimetry (TG) and differential scanning
calorimetry (DSC)
For the thermal analysis, a DSC/TG Netzsch STA 449 F3
Jupiter was used. The TG and DSC studies were carried
out with a simultaneous DSC/TG apparatus thermal analyzer,
at 1 C min1, from 20 C to 450 C. Dry nitrogen at a ﬂow
rate of 50 mL min1 was used as the purge gas. Alumina cru-
cibles were used as the sample holder (5 mg).
2.6.5. X-ray powder diffraction (XRPD)
X-ray diffraction patterns of MAB were obtained using a h–h-
ray diffractometer (Xpert Pro Multi-Purpose Diffractometer,
PanAnalytical) equipped with Ka copper radiation
(k= 1.5418 A˚), operating with 40 mA current and 45 kV volt-
age, sample spinner and a Real Time Multiple Strip (RTMS)
detector. The measurements were taken at room temperature,
scanning 2h from 4 to 35, with a 0.016 step size and 25.0 s
step time.
2.6.6. Scanning electron microscopy
Due to the fact that MAA is an oil, SEM analyses were possi-
ble only for MAB powder. The sample surface was coated with
a layer of gold with a thickness of 8–10 nm by sputtering using
a Baltec (Liechtenstein, Switzerland) SCD 005 equipment, and
then analyzed in a Philips (Hillsboro, U.S.A.) XL 30 electron
microscope with a voltage of 10 kV. Photomicrographs were
taken with 105, 500 and 1000-fold magniﬁcation.
3. Results and discussion
In addition to the chemical characterization ofMAA andMAB
we carried out physicochemical and stability studies. The latter
studies are more commonly applied to synthetic or nanocom-
posites (Hattab and Benharrats, 2015); however, the impor-
tance of this characterization of natural compounds relates to
their potential as phytodrugs or even as leading molecules to
optimization in pharmaceutical chemistry, aiming the improve-
ment of its pharmacodynamic/pharmacokinetic aspects.
3.1. Structural characterization
In order to conﬁrm the chemical structure of MAA and MAB,
it was carried out the spectroscopic and spectrometric analysis
of NMR (1H and 13C), FTIR and UV. In addition, it was
determined, for the ﬁrst time, the fragmentation patterns by
mass spectrometry and the Raman spectroscopy.
3.1.1. Nuclear magnetic resonance 1H and 13C
Spectral Data for AMA: 1H NMR (CDCl3, 300 MHz) d: 1.60
(3H, s, H-100), 1.69 (3H, s, H-80), 1.77 (9H, s, H-400, 500, 90), 2.11
(2H, m, H-50), 3.38 (2H, t, J= 6.0 Hz), 3.39 (2H, t,
J= 6.0 Hz), 5.08 (1H, m, H-60), 5.32 (2H, t, J= 7.0 Hz,
2H0, 200), 7.77 (2H, s, H-2, H-6). 13C NMR (CDCl3,75,5 MHz) d: 16.2 (C-90), 17.9 (C-100, 400), 25.7 (C-80), 25.8
(C-500), 26.3 (C-50), 29.3 (C-100), 29.7 (C-10), 39.7 (C-40), 121.0
(C-1), 121.2 (C-20), 121.4 (C-200), 123.8 (C-60), 127.0 (C-3,
C-5), 130.5 (C-2, C-6), 131.8 (C-70), 134.0 (C-300), 139.1
(C-30), 158.0 (C-4), 172.0 COOH.
Spectral Data for AMB: 1H NMR (CDCl3, 300 MHz) d:
1.30 (3H, s, H-70), 1.55 (2H, m, H-20), 1.63 (3H, s, H-80),
1.69 (3H, s, H-60), 1.72 (3H, s, H-500), 1.73 (3H, s, H-400), 2.17
(2H, m, H-30), 3.17 (2H, dd, J= 16.0, 9.2 Hz, H-3), 3.29
(2H, m, H-100), 4.74 (1H, t, J= 9.2 Hz, H-2), 5.12 (1H, t,
J= 7.2 Hz, H-40), 5.28 (1H, t, J= 7.2 Hz, H200), 7.75 (2H, s,
H-4, H-6). 13C NMR (CDCl3, 75.5 MHz) d: 17.7 (C-80), 17.9
(C-500), 22.0 (C-30), 22.6 (C-70), 25.6 (C-400), 25.7 (C-60), 28.3
(C-100), 29.9 (C-3), 37.1 (C-20), 73.8 (C-10), 89.6 (C-2), 121.4
(C-200), 121.8 (C-5), 123.1 (C-3a), 124.0 (C-40), 125.0 (C-6),
127.2 (C-7), 131.4 (C-4), 132.2 (C-50), 133.2 (C-300), 162.4
(C-7a), 171.7 (C8).
The NMR 1H and 13C spectral data obtained for myrsinoic
acids A and B were consistent with the literature (Bella-Cruz
et al., 2013; Hess et al., 2010; Hirota et al., 2002; Makabe
et al., 2003).
Since the structure of MAB presents two chiral centers, 2D
Nuclear Overhauser Effect Spectroscopy (NOESY) and
proton nuclear magnetic resonance spectroscopy (NMR) were
applied, to determine the relative conﬁgurations of the
diastereomers (see supplementary material).
3.1.2. Fourier transform infrared spectroscopy (FTIR)
The MAA ATR-FTIR spectrum, presented in Fig. 2A,
showed absorption peaks at 2918 cm1, corresponding to
CHsp3 stretch. A broad overlapping OH band in the range of
3400–2600 cm1 was observed, which together with the peak
at 1678 cm1 (C‚O), characterizes the carboxylic acid. At
1600 cm1 and 1201 cm1, the peaks observed correspond to
the C‚C and CAO stretch. The DRS-FTIR spectrum for
MAB, shown in Fig. 2B, displayed a stretch peak at
3367 cm1 with OAH corresponding to alcohol. A prominent
absorption band between 3000 and 2600 cm1 and intense
peak at 1701 cm1 correspond to carboxylic acid. The peak
at 1605 cm1 corresponds to the C‚C stretch, conﬁrmed by
the intense bending peak at 960 cm1. The 1282 and
1180 cm1 bands correspond to the CAO stretch, concerning
aryl-alkyl-ether in the molecule.
3.1.3. Raman spectroscopy
Raman spectroscopy is an analytical technique that is widely
applied to the chemical and physicochemical characterization
of solid compounds as it is a non-destructive method and
needs only minimal sample preparation. Furthermore, in con-
trast to IR spectroscopy, it is not disturbed by the presence of
water. Raman spectra are a highly speciﬁc method, serving as
the ﬁngerprints of the molecules (La´ng et al., 2013). Raman
spectroscopy was performed complementary to DRIFT, with
the purpose of elucidating and conﬁrming the compound
structure. The MAB Raman spectrum is presented in Fig. 3.
It showed the main characteristic bands at 1700–1500 cm1,
relating to the aromatic ring and COOH vibrations,
respectively, in 1400 cm1 the vibration relative to CH3CH2,
and the double bond signal is demonstrated at 1300 cm1,
which is in agreement with the previous data (Vandenabeele
et al., 2000).
Figure 2 FTIR spectra of myrsinoic acid A (A) and myrsinoic acid B (B).
Figure 3 Raman spectrum of MAB.
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The MAA UV spectrum (Fig. 4) presented two maximum
absorption peaks, at approximately 205 and 258 nm. MAB
showed maximum absorption at 218 and 269 nm (Fig. 4).
Speciﬁc absorption (E1%1cm) was 287.2 and 229.0 for MAA and
MAB, respectively.
3.1.5. Mass spectrometry with direct sample inlet (DI-MS)
The insertion of MAA into the mass spectrometer resulted in a
spectrum (Fig. 5A) with a molecular ion peak at m/z 342 and a
base peak at m/z 123, which was generated by cleavage
between C10 and C20 bond (C9H5). The MAB mass spectrum
(Fig. 5B) showed the molecular ion peak at m/z 358 and the
base peak at m/z 69 corresponding to the fragment (C5H9),
generated by the cleavage of the C10 0 and C7 bond. For this
compound, an intense peak was observed at m/z 109, which
is suggestive of the C10 and C2 cleavage bond, with loss of
water.
3.2. HPLC analysis
The HPLC method was developed considering the parameters
of resolution factor (R) between peaks, runtime and the capac-
ity of being stability-indicative. The use of an acid mobilephase was required. MAA and MAB had retention times
(RT) of 16.03 ± 0.01 and 15.47 ± 0.01 min, respectively
(Fig. 4). Separation was considered satisfactory (R= 4.3).
The calculated purity of MAA was 76.20% and MAB of
98.90%. It was not observed supplementary peaks in another
wavelength (200–400 nm), for both compounds. The HPLC
method showed good speciﬁcity, as the peak purity through
Figure 4 (A) Chromatographic proﬁles of MAA at 260 nm (RT of 16.03 min), and of MAB at 270 nm (RT of 15.47 min) and its
respective UV spectra; Chromatographic proﬁles of MAA at 260 nm (B) and MAB at 270 nm (C) after degradation studies: (1) non-
degraded samples at 100 lg mL1; (2) samples after stress with 1 M HCl 24 h; (3) samples after stress with 1 M NaOH 24 h; (4) samples
after stress with 30% H2O2 6 h; (5) samples after stress with visible light (2.4 mi lux h
1); (6) and samples after stress with UVA
(400 W h m2).
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apparent co-elution of degradation products with MAA and
MAB peaks after the stress tests described below.
3.3. Stability data
After dissolved in the degraded solutions, both compounds
remained visually soluble. Signiﬁcant degradation was observed
after acid hydrolysis (1 M HCl, 24 h) of MAA (72.22%) and
MAB (43.44%). Chromatographic proﬁle of degraded MAA
showed the presence of at least six different impurities with
RT between 12.4 and 15.3 min, as observed in Fig. 4A-2. The
MAB chromatogram after acid hydrolysis presented seven
impurity peaks between 11.2 and 17.1 min (Fig. 4B-2).
Degradation was not observed when MAA and MAB were
exposed to alkaline hydrolysis condition (Fig. 4A-3 and B-3,
respectively), probably due to the formation of a stable salt.MAA submitted to oxidative hydrolysis (30% H2O2, 6 h),
showed signiﬁcant degradation (36.60%), and supplementary
peaks were observed at about 12.63 and 12.88 min (Fig. 4A-
4). MAB exposed to the same conditions exhibited degradation
of 6.80%, and supplementary peaks were detected at 14.06 and
14.33 min (Fig. 4B-4).
After visible light exposure (2.4 mi lux h1) of the MAA
sample, the yellowness of the oil decreased. Its chromato-
graphic analysis showed a signiﬁcant degradation of 40.74%
and a different peak with RT about 14.0 min (Fig. 4A-5).
When MAB was submitted at this stress condition, a color
change was observed in the white powder, which turned yel-
low. The HPLC proﬁle, presented in Fig. 4B-5, showed a
MAB degradation of 29.93% and elution of the degradation
products at between RT 12.8 and 14.6 min. When MAA was
exposed to UVA irradiation (400 W h m2), the oil presented
a dark yellow coloration and degradation of 45.01% was
Figure 5 DI-MS (EI mode) mass spectrum of MAA (A) and
MAB (B) and suggested major fragmentation mechanisms.
Figure 6 Correlation between logP and logk was determined by
the isocratic method for reference compounds: benzyl alcohol,
phenol, benzoic acid, benzene, toluene and naphthalene.
878 T. Zermiani et al.observed. As observed in Fig. 4A-6, the same impurities were
observed, which appeared after visible light exposure, at RT of
14.08 min. MAB presented color change to dark yellow after
UV exposure. This compound also had signiﬁcant degradation
(21.97%), and the same degradation products were observed at
between RT 12.8 and 14.6 min (Fig. 4B-6), for the MAB after
visible light exposure.
The temporal stability test indicates that the MAA and
MAB methanol solutions were stable when stored at light
shielding at room temperature until 14 days. MAB acetonitrile
solutions showed stability at the room temperature, after
14 days. However signiﬁcant degradation of MAA acetonitrile
solution was observed after 14 days, and no change in the
chromatographic proﬁle of MAA, probably due to the
formation of nonchromophore degradation products.
Both MAA and MAB in methanol or acetonitrile solutions
were stable until 14 days, when stored at light shielding at 2 C
or 15 C. The statistical results showed no signiﬁcant differ-
ence among samples. The RSD (%) for assay of MAA and
MAB during solution stability was within <2%.
3.4. Physicochemical characterization
Using HPLC, the partition coefﬁcients (logP) of each com-
pound were determined by plotting the logP values against
(logk) of the known compounds (Fig. 6) (OECD, 1989), where
t0 was 3.31 min.
The following calibration curve was obtained:
log Pow ¼ 2:1311  log kþ 2; 244 (r2 ¼ 0:8773; n ¼ 6). MAA
and MAB exhibited logk values of +0.52 and +0.48, in that
order, and the logP values were 3.30 and 3.22, respectively.
These data are extremely useful in the drugs biopharmaceu-
tical classiﬁcation. The literature reports that compounds withlogP of between 2 and 3 show optimum skin permeability
coefﬁcient values (Hadgraft et al., 2000). LogP values found
for MAA and MAB were similar to those of non-steroidal
anti-inﬂammatory agents (NSAIDs) such as diclofenac,
ibuprofen, indomethacin and naproxen, which showed signiﬁ-
cant skin permeability after topical application (Hadgraft
et al., 2000; Singh and Roberts, 1994).
Lipophilicity is one of the most important descriptors to be
identiﬁed for CNS penetration. Blood-brain barrier (BBB)
penetration is considered optimal when the logP values are
in the range of 1.5–2.7, with a mean value of 2.1 (Pajouhesh
and Lenz, 2005). However, it is seen that CNS drugs differed
considerably in their lipophilicity, not following this rule.
For example, some antidepressants present a mean logP of
3.10 (Ghose et al., 1999), as well as some drugs used in the
treatment of Alzheimer’s disease, such as donepezil (logP
value of 3.08–4.11) (Sozio et al., 2012) and Memantine, which
has a logP value of 3.28 (Sonkusare et al., 2005). Thus, the
logP of MAA can support the effects on memory observed
in a previous study conducted by our research group (Costa
et al., 2003). The absorption, excretion, and physiological bar-
rier penetration may be related to the logP and pKa values of
drug, highlighting the importance of predicting both of these
parameters in drugs.
TGAs of MAA revealed no mass loss from the sample over
temperature range of 20–150 C (Fig. 7A). Upon heating,
MAA displayed a gradual loss of mass between 160 C and
400 C, maintained until 450 C. The results evidence the low
humidity of 1.42 ± 0.75% for this compound. The DSC ther-
mogram for MAA showed an exothermic event at
272.1 ± 9.09 C (Fig. 7A), characteristic of the process of
thermal decomposition that occurs concomitant to heat
release. As myrsinoic acid A is an oil, it was not possible
observe its melting peak; thus, purity could not be ascertained
using DSC.
The TGA plot of MAB shows that thermal degradation of
the sample starts at 250 C, with a progressive loss of mass
until 350 C, maintained up to 450 C (Fig. 7B). The MAB
humidity was 0.75 ± 0.01%. The DSC thermogram showed
a sharp endothermic peak with maximum at 123.6 ± 0.1 C,
due to the compound melting (Fig. 7B). The exotherm event
at 298.6 ± 10.3 C corresponded to signiﬁcant loss of mass
and thermal degradation. The purity of MAB was determined
as 100.74 ± 0.18 mol%, by the Van’t Hoff equation.
The active pharmaceutical ingredient (API) can exist in dif-
ferent crystalline forms. Formulators should take advantage of
Figure 7 DSC and TG thermograms of MAA (A) and MAB (B).
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and biopharmaceutical properties of APIs need to be
improved. The literature contains many examples of the suit-
ability of using one crystalline form as opposed to another
(Martino et al., 2007). In general, amorphous structure pre-
sents greater solubility than crystalline form, which is a desir-
able characteristic for a new pharmaceutical compound. As an
example, low levels of amorphous character induced in griseo-
fulvin by milling, increased its solubility of twofold or more
(Elamin et al., 1994). The X-ray diffraction patterns related
to myrsinoic acid B are shown in Fig. 8A. According to the
diffractograms, it is possible to observe a semi-crystalline
behavior for the sample, with an evident reﬂection at 5.2, atFigure 8 X-ray diffraction spectra (A) and SEM photomlow 2h angles. These results, taken together with the DSC data,
indicate that the phenolic compound MAB presents a semi-
crystalline structure, what means that the sample has two
phases, crystalline and amorphous.
The morphological analysis of drugs is an easy way to mon-
itor and detect changes related to variations in crystal synthesis
process or even in pharmaceutical processing (Maximiano
et al., 2010). The photomicrograph of Fig. 8B shows the mor-
phology of MAB crystallized by a solution of hexane–ethyl
acetate (8:2) evaporated at room temperature with magniﬁca-
tion of 1000·. It indicates a semi-crystalline compound, with
the presence of some crystals with an orthorhombic
appearance and particles without deﬁned shape, which isicrograph (enlargement of 1000·) (B) of MAB powder.
880 T. Zermiani et al.characteristic of an amorphous compound, and is in agreement
with the previous results (DSC and XRPD).
Finally, the solubility analysis of markers revealed that
MAA was very slightly soluble in methanol and acetonitrile,
while MAB was slightly soluble in both solventes. Both mark-
ers were practically insoluble in water.
4. Conclusions
Knowledge of the chemical, physical and physicochemical
properties of MAA and MAB characterized in the present
study will enable the use of these compounds as analytical
standards, and will contribute to the development and quality
control of new phytodrugs. This information will also con-
tribute to preformulation studies and the prediction of phar-
macokinetic properties.Acknowledgments
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Appendix A. Supplementary material
As presented in Fig. 9A, NOESY correlations were observed
from H-2 to H-70, H-20 and H-30. This demonstrates that the
hydrogens H-2 and H-70 are on the same side of the molecule.
NOESY correlations from H-20 to H-30 and to H-40, and from
H-30 to H-70 were also observed. Based on a 2D NOESY
experiment, two possible relative conﬁgurations were deduced,
as shown in Fig. 9B. Supplementary data associated with this
article can be found, in the online version, at http://dx.doi.org/
10.1016/j.arabjc.2015.06.032.
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